Welcome to our dedicated page for Scinai Immunotherapeutics Ltd. SEC filings (Ticker: SCNI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) files its regulatory reports as a foreign private issuer with the U.S. Securities and Exchange Commission, primarily through annual reports on Form 20‑F and current reports on Form 6‑K. This page provides access to those SEC filings, along with AI-assisted tools that help explain their contents in clear language.
In its 20‑F annual report, Scinai presents audited financial statements, a description of its dual business model in I&I biologics and CDMO services, risk factors, and details on capital structure and governance. The company’s 6‑K filings furnish interim information such as quarterly and half‑year financial results, business updates on Scinai Bioservices and the I&I pipeline, grant awards, and material agreements, including Standby Equity Purchase Agreements with Yorkville Advisors.
Recent 6‑Ks also describe grant applications and decisions related to programs like PC111, a human anti‑Fas Ligand monoclonal antibody in development via an option to acquire Pincell Srl, and governance matters such as changes in board composition and independent registered public accounting firms as part of cost-cutting measures. Other 6‑Ks incorporate press releases on Israel Innovation Authority funding for an advanced fill‑and‑finish system and business updates for the first half of 2025.
On Stock Titan, investors can review these filings in chronological order and use AI-powered summaries to quickly understand key points in lengthy documents. The platform highlights important elements in Scinai’s filings, such as financing arrangements, grant-related disclosures, and updates on its I&I and CDMO operations, helping readers navigate complex regulatory language without replacing the full text of the original SEC documents.
Scinai Immunotherapeutics files its annual report outlining severe financial stress and substantial doubt about its ability to continue as a going concern. As of December 31, 2025, cash and cash equivalents were $1.6 million against an accumulated deficit exceeding $120 million and continued operating losses.
The company runs both a contract development and manufacturing (CDMO) unit and early-stage NanoAb therapeutic programs, neither of which currently generates sufficient revenue. It highlights major execution, financing, regulatory, clinical, competitive and CDMO integration risks that could force it to cut activities or cease operations.
Scinai Immunotherapeutics Ltd. Chief Operating Officer Mark Elad has filed an initial ownership report showing a substantial equity position. He directly holds 160,355,016 Ordinary Shares, which include large restricted share unit (RSU) awards granted in January 2024 and November 2025 that vest over multiple years subject to continued service.
He also holds American Depositary Shares representing 13,460,984 underlying Ordinary Shares, convertible at any time with no expiration date. The filing records holdings only and does not report any recent share purchases or sales.
Scinai Immunotherapeutics has signed a Second Amendment to its Binding Option Agreement to acquire PinCell and aligned the option timelines with a European grant process. The deadline to meet option conditions is now August 31, 2026, with an exercise period through September 30, 2026.
Scinai also submitted a revised application to the FENG SMART Path program seeking €12 million in non-dilutive, non‑repayable funding to co-finance a €15 million R&D program for PC111, targeting severe autoimmune skin diseases. A funding decision is expected in about three to four months and, if awarded, could support early clinical development and human proof of concept while limiting shareholder dilution.
Scinai Immunotherapeutics Ltd. reported that it received a written notice from the Nasdaq Listing Qualifications Department on March 12, 2026 stating that its American Depositary Shares are not in compliance with the Nasdaq Capital Market’s minimum bid price requirement, because the closing bid price was below $1.00 for 30 consecutive business days.
The notice does not immediately affect the listing or trading of the ADSs. Scinai has 180 calendar days, until September 8, 2026, to regain compliance, which will occur if the closing bid price is at least $1.00 for a minimum of ten consecutive business days. The company plans to monitor its share price and evaluate options to regain compliance.
Scinai Immunotherapeutics Ltd. director Yael Margolin filed an initial ownership report showing existing equity interests rather than new trades. Margolin directly holds 50 American Depositary Shares, which are convertible at any time into 200,000 Ordinary Shares and have no expiration date.
In addition, Margolin holds stock options over 1,720,000 and 8,000,000 Ordinary Shares at an exercise price of $0.0050 per share, expiring on August 24, 2033, and options over 48,200,000 Ordinary Shares at an exercise price of $0.0004 per share, expiring on December 22, 2035. These options vest in annual installments beginning on August 24, 2024, August 24, 2027, and December 22, 2026, subject to continued service.
Scinai Immunotherapeutics Ltd. director Uri Ben-Or filed an initial ownership report showing substantial equity holdings. He directly beneficially owns 33,329,004 Ordinary Shares, including several large restricted share unit (RSU) grants that vest over multiple years, subject to his continued service. These include 4,425,004 Ordinary Shares in RSUs granted on January 25, 2024, 904,000 Ordinary Shares in RSUs granted on November 21, 2024, and 28,000,000 Ordinary Shares in RSUs granted on November 12, 2025, each with specified multi-year vesting schedules. He also holds 630 American Depositary Shares, which are convertible at any time into 2,519,344 Ordinary Shares with no expiration date.
Scinai Immunotherapeutics Ltd. director Samuel J. Moed filed an initial ownership report showing existing equity interests. He holds 50 American Depositary Shares convertible into 200,000 Ordinary Shares at any time with no expiration date, plus stock options over 4,000,000, 8,000,000 and 48,200,000 Ordinary Shares at exercise prices of $0.0050 and $0.0004 per share. These options vest in annual installments beginning on August 24, 2024, August 24, 2027 and December 22, 2026, contingent on his continued service, and expire between 2033 and 2035.
Scinai Immunotherapeutics Ltd. director Mark Germain reported his initial holdings of stock options in the company. He holds three option awards that together are exercisable for 11,628,400 Ordinary Shares at an exercise price of 0.0050 and 16,000,000 Ordinary Shares at an exercise price of 0.0050, both expiring on 2033-08-24, and 100,000,000 Ordinary Shares at an exercise price of 0.0004 expiring on 2035-12-22.
One option vests in a single installment on August 24, 2027, while the others vest in three equal annual installments starting August 24, 2024 and December 22, 2026, in each case conditioned on Mr. Germain’s continued service. The filing notes that the Ordinary Shares are represented by American Depositary Shares, each currently representing four thousand Ordinary Shares.
Scinai Immunotherapeutics Ltd. director Green Jay has reported initial holdings in connection with becoming an insider. The filing shows direct ownership of 50 American Depositary Shares, which are convertible at any time into 200,000 Ordinary Shares and have no expiration.
Green Jay also holds stock options over 1,000,000 Ordinary Shares and 8,000,000 Ordinary Shares at an exercise price of $0.0050 per share, expiring on August 24, 2033, plus options over 48,200,000 Ordinary Shares at an exercise price of $0.0004 per share, expiring on December 22, 2035. These options vest in installments between August 24, 2025 and December 22, 2027, subject to continued service.
Scinai Immunotherapeutics Ltd. director and Chief Executive Officer Amir Reichman filed an initial Form 3 showing his beneficial ownership in the company. He reports direct holdings of 311,637,600 Ordinary Shares, which include restricted share units granted in January 2024 and December 2025 that vest over several years, subject to his continued service. He also holds 16,885 American Depositary Shares that are convertible at any time into 67,540,000 Ordinary Shares at no stated expiration date.